Deutsche Biotech Innovativ AG
Deutsche Biotech Innovativ AG: First public offer to private investors
DGAP-News: Deutsche Biotech Innovativ AG / Key word(s): Capital Increase CORPORATE NEWS Capital increase Deutsche Biotech Innovativ AG: – Offer of up to 596,440 shares to private investors at a price of 33.50 euro per share – Subscription period is expected to end on 11 November 2015 Hennigsdorf, 29 October 2015 – In the course of the ongoing capital increase of Deutsche Biotech Innovative AG (“DBI AG”) private investors can now for the first time subscribe for the company’s shares. After expiry of the subscription period for existing shareholders on 28 October, the subscription period for private investors is expected to run until and including 11 November 2015. The lead product is the patented drug Adrecizumab to reduce mortality by organic failure in septic shock. Although each year approximately 8 million people die of it, there is currently no approved drug worldwide. Adrecizumab has successfully passed the preclinical phase and will be tested in a Phase I trial as from the end of 2015. Further information: A current research study on DBI from First Berlin Equity Research is available on the Deutsche Biotech Innovativ AG website via the following link: The BaFin-approved prospectus is also available on the website:
Both members of DBI AG’s Management Board, Dr Bernd Wegener and Dr. Andreas Bergmann, have many years of experience in the biotechnology field. Both were founders and part of the management team of B.R.A.H.M.S. AG, a highly successful biotechnology company specialized in blood biomarkers. It was sold in 2009 for around 330 million euro. Dr. Bernd Wegener is also a member of the Executive Board of the Association of the German Pharmaceutical Industry (Bundesverband der Pharmazeutischen Industrie). For more information, please contact: Deutsche Biotech Innovativ AG Kirchhoff Consult AG DISCLAIMER This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in the United States of America (the “United States”), Australia, Canada or Japan or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to in this announcement will not be and have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements under the U.S. Securities Act. Subject to certain exceptions, the securities referred to in this announcement may not be offered or sold in Australia, Canada or Japan, or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. The offer and sale of the securities referred to in this announcement has not been and will not be registered under the U.S. Securities Act or under the applicable securities laws of Australia, Canada or Japan. There will be no public offer of the securities in the United States. The public offer in Germany will solely be made by means of and on the basis of a securities prospectus published on 8 October 2015. The securities prospectus is available free of charge at the Company’s website under http://www.dbi-ag.de/investoren-presse/kapitalerhoehung-2015/ and at the headquarters of DBI AG in Hennigsdorf. 2015-10-29 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
407077 2015-10-29 |